NIH IRP Inventions Have High Public Health Impact

NIH-OTT authors report in Nature Biotechnology (Jan 2014) an analysis of FDA approved drugs and biologics that utilize inventions licensed from the NIH Intramural Research Program (IRP).   Compared with other public-sector research institutions in the US, the NIH-IRP contribution has had a disproportionately greater impact on the overall number of products produced, drugs granted orphan status and drugs granted priority review.  See http://www.nature.com/nbt/journal/v32/n1/pdf/nbt.2785.pdf.